Basulin, a long-acting formulation of human insulin based on medusa nanoparticles

Abstract

• Basulin® is the only once-a-day human insulin with a proof of efficacy in human clinical trials. • Basulin has demonstrated a good safety and tolerability and confirmed the 24 hours efficacy in Phase IIa during 14 days with 20 patients. • Basulin maintains the full activity of human insulin as a human growth hormone essential to reduce long-term complications associated with the lack of insulin (retinopathy, heart attack, amputation, etc...) compare to other strategies of insulin analogues (insulin glargine, insulin determir). • Basulin® offers all the advantages of the present systems of injection (pen, syringe with 31tw gauge needle). • The insulin market continues to grow significantly. • Basulin® could reach the market in 2009 and is protected by patents until 2024. • Basulin® is available for licensing worldwide.